Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00929864 · ClinicalTrials.gov registry record · Phase 3
Abatacept Versus Adalimumab Head-to-Head
A Phase 3 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 869
- Enrollment target
NCT00929864 is a Phase 3 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 869 participants.
The verdict
NCT00929864, a Phase 3 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 869 participants
- Enrollment target
Study Summary
The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
Interventions
- DRUG Abatacept
- DRUG Adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 869 participants |
| Start Date | 2009-10 |
| Est. Completion | 2012-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00929864
The ClinicalTrials.gov registry entry for NCT00929864 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 869 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT00929864 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00929864 about?
NCT00929864 is a clinical study titled "Abatacept Versus Adalimumab Head-to-Head". The purpose of this study is demonstrate that subcutaneous abatacept is non-inferior (no worse than) to subcutaneous adalimumab in the treatment of subjects with rheumatoid arthritis who are biologic naive
What is the current status of trial NCT00929864?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 869 participants. The study started on 2009-10. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00929864?
The interventions under investigation include: Abatacept (DRUG), Adalimumab (DRUG).
Who is sponsoring clinical trial NCT00929864?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.